🇺🇸 ABBV — AbbVie Inc.

Healthcare Compra
← Volver

Precio actual

256,46 USD

Máx. histórico

267,47

37 días

Caída desde máximo

-4,12%

Rango 52 semanas

190,75 – 267,47

Variación hoy

-1,44%

Cierre anterior

260,21

Rango de hoy

255,61 – 258,91

Volumen hoy

4.701.126

Información
Nombre completo
AbbVie Inc.
Divisa
USD
Mercado
NYSE
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
57.000
PER ⓘ
72,45 (puede no estar actualizado)
Dividend yield
2,70% (puede no estar actualizado)
Precio objetivo analistas
276,59 USD (puede no estar actualizado)
Primera cotización
02/01/2013
Precio actualizado
hace 1 día
Sobre la empresa

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Dividendos repartidos Total últimos 12 meses: 6,8300 USD · Yield: 2,66%
Fecha de pago Importe por participación
15/07/2026 1,7300 USD
15/04/2026 1,7300 USD
16/01/2026 1,7300 USD
15/10/2025 1,6400 USD
15/07/2025 1,6400 USD
15/04/2025 1,6400 USD
15/01/2025 1,6400 USD
15/10/2024 1,5500 USD
15/07/2024 1,5500 USD
12/04/2024 1,5500 USD
12/01/2024 1,5500 USD
12/10/2023 1,4800 USD
13/07/2023 1,4800 USD
13/04/2023 1,4800 USD
12/01/2023 1,4800 USD
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
19/04/2016 60,09 61,23 59,67 60,17 +0,48% 2,60% 6.149.300
18/04/2016 59,50 60,32 59,30 59,88 +0,62% 1,71% 6.089.400
15/04/2016 59,55 59,74 58,78 59,51 +0,39% 1,61% 4.660.800
14/04/2016 59,15 59,49 59,00 59,28 +0,37% 0,83% 5.185.600
13/04/2016 59,87 60,00 58,70 59,06 -1,39% 2,17% 7.023.000
12/04/2016 58,98 60,05 58,69 59,89 +2,38% 2,31% 7.243.700
11/04/2016 58,59 59,25 58,25 58,50 +0,05% 1,71% 4.894.000
08/04/2016 59,49 59,80 58,17 58,47 -1,40% 2,74% 5.750.000
07/04/2016 59,42 59,90 58,76 59,30 -0,99% 1,92% 7.827.600
06/04/2016 58,52 59,90 58,52 59,89 +2,31% 2,36% 6.322.800
05/04/2016 58,54 59,56 58,09 58,54 -1,13% 2,51% 6.779.400
04/04/2016 57,64 59,40 57,49 59,21 +3,12% 3,31% 8.108.100
01/04/2016 56,58 57,57 56,36 57,42 +0,53% 2,14% 4.525.700
31/03/2016 57,02 57,46 56,82 57,12 +0,21% 1,12% 4.930.300
30/03/2016 57,43 57,53 56,72 57,00 -0,09% 1,41% 3.650.300
29/03/2016 56,10 57,10 55,22 57,05 +1,68% 3,35% 4.567.900
28/03/2016 56,35 56,70 55,80 56,11 -0,02% 1,60% 3.803.100
24/03/2016 56,14 56,25 55,67 56,12 -0,43% 1,03% 5.278.900
23/03/2016 57,16 57,50 56,22 56,36 -1,98% 2,24% 5.116.400
22/03/2016 55,75 57,54 55,75 57,50 +2,66% 3,21% 7.661.600
21/03/2016 56,52 56,78 55,73 56,01 -0,99% 1,86% 6.632.900
18/03/2016 55,59 56,60 54,80 56,57 +2,26% 3,24% 11.029.800
17/03/2016 56,46 56,46 54,41 55,32 -1,76% 3,63% 8.308.800
16/03/2016 55,58 56,54 55,25 56,31 +1,24% 2,32% 6.245.400
15/03/2016 56,65 56,93 55,13 55,62 -2,78% 3,18% 5.779.600
14/03/2016 57,67 57,73 56,97 57,21 -0,90% 1,32% 4.650.800
11/03/2016 56,40 57,87 56,35 57,73 +2,67% 2,70% 6.537.400
10/03/2016 56,56 57,37 55,32 56,23 -0,28% 3,62% 5.627.900
09/03/2016 55,51 56,65 55,04 56,39 +1,93% 2,90% 8.402.500
08/03/2016 56,18 56,47 55,23 55,32 -1,91% 2,21% 5.303.700